BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11297258)

  • 1. Screening for and identification of novel agents directed at renal cell carcinoma.
    Mertins SD; Myers TG; Hollingshead M; Dykes D; Bodde E; Tsai P; Jefferis CA; Gupta R; Linehan WM; Alley M; Bates SE
    Clin Cancer Res; 2001 Mar; 7(3):620-33. PubMed ID: 11297258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma.
    Köpf-Maier P
    Anticancer Res; 1999; 19(1A):493-504. PubMed ID: 10226588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.
    Kadhim SA; Bowlin TL; Waud WR; Angers EG; Bibeau L; DeMuys JM; Bednarski K; Cimpoia A; Attardo G
    Cancer Res; 1997 Nov; 57(21):4803-10. PubMed ID: 9354442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The alkylator treosulfan shows activity towards human renal-cell carcinoma in vivo and in vitro.
    Köpf-Maier P
    In Vivo; 1998; 12(3):275-88. PubMed ID: 9706471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1.
    Loaiza-Pérez AI; Kenney S; Boswell J; Hollingshead M; Hose C; Linehan WM; Worrell R; Rubinstein L; Sausville EA; Vistica DT
    J Urol; 2004 Apr; 171(4):1688-97. PubMed ID: 15017268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
    Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
    Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
    Plonowski A; Schally AV; Nagy A; Kiaris H; Hebert F; Halmos G
    Cancer Res; 2000 Jun; 60(11):2996-3001. PubMed ID: 10850448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells.
    Sato H; Senba H; Virgona N; Fukumoto K; Ishida T; Hagiwara H; Negishi E; Ueno K; Yamasaki H; Yano T
    Mol Carcinog; 2007 Mar; 46(3):215-24. PubMed ID: 17186540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cytotoxicity of methyl protoneogracillin (NSC-698793) and gracillin (NSC-698787), two steroidal saponins from the rhizomes of Dioscorea collettii var. hypoglauca, against human cancer cells in vitro.
    Hu K; Yao X
    Phytother Res; 2003 Jun; 17(6):620-6. PubMed ID: 12820229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
    Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
    Clin Cancer Res; 2005 Aug; 11(15):5549-57. PubMed ID: 16061872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The hollow fiber assay: continued characterization with novel approaches.
    Hall LA; Krauthauser CM; Wexler RS; Hollingshead MG; Slee AM; Kerr JS
    Anticancer Res; 2000; 20(2A):903-11. PubMed ID: 10810375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical antitumor activity of the oral platinum analog satraplatin.
    Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines.
    Efferth T; Sauerbrey A; Halatsch ME; Ross DD; Gebhart E
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):56-67. PubMed ID: 12616342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations.
    Fojo T; Farrell N; Ortuzar W; Tanimura H; Weinstein J; Myers TG
    Crit Rev Oncol Hematol; 2005 Jan; 53(1):25-34. PubMed ID: 15607933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel class of lipophilic quinazoline-based folic acid analogues: cytotoxic agents with a folate-independent locus.
    Skelton LA; Ormerod MG; Titley J; Kimbell R; Brunton LA; Jackman AL
    Br J Cancer; 1999 Apr; 79(11-12):1692-701. PubMed ID: 10206279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cytotoxicity of methyl protoneodioscin (NSC-698791) against human cancer cell lines in vitro.
    Hu K; Yao XS
    Anticancer Res; 2002; 22(2A):1001-5. PubMed ID: 12014616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant antitumoral activity of cationic multilamellar liposomes containing human IFN-beta gene against human renal cell carcinoma.
    Nakanishi H; Mizutani Y; Kawauchi A; Ukimura O; Shiraishi T; Hatano M; Mizuno M; Yoshida J; Miki T
    Clin Cancer Res; 2003 Mar; 9(3):1129-35. PubMed ID: 12631618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic effects of monoclonal antibody-beta-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma.
    Svensson HP; Frank IS; Berry KK; Senter PD
    J Med Chem; 1998 Apr; 41(9):1507-12. PubMed ID: 9554883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo.
    Yuasa T; Nogawa M; Kimura S; Yokota A; Sato K; Segawa H; Kuroda J; Maekawa T
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):853-9. PubMed ID: 15701876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
    Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
    Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.